|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
In older women, those with the CYP 19 GA and GG genotypes had an increased prevalence of osteoporosis (P = 0.04) and fractures (P = 0.003).
|
14715870 |
2004 |
|
Osteoporosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The women with lower aromatase activity may have greater likelihood of PMOP and the E<sub>2</sub>/T was expected to be a valuable indicator for the prediction of PMOP and to monitor the process of osteoporosis.
|
29329467 |
2018 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Despite their effectiveness in reducing tumor recurrence, aromatase inhibitors have adverse effects on the cardiovascular system and increase osteoporosis and bone fractures.
|
25023195 |
2014 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
Thus, aromatase is an attractive osteoporosis candidate gene.
|
17391072 |
2007 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In older women, those with the CYP 19 GA and GG genotypes had an increased prevalence of osteoporosis (P = 0.04) and fractures (P = 0.003).
|
14715870 |
2004 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Thus, aromatase is an attractive osteoporosis candidate gene.
|
17391072 |
2007 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In multivariable analyses, osteoporosis was positively associated with the aromatase inhibitor (AI) sequential treatment after tamoxifen (HR, 3.14; 95% CI, 1.44-6.88; P = .004) but was more pronounced with AI use as upfront monotherapy (HR, 5.53; 95% CI, 1.46-20.88; P = .012).
|
30413856 |
2019 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Furthermore, current therapies using aromatase inhibitors have side effects on bone resulting in development of osteoporosis in some patients.
|
17215075 |
2007 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Dysfunction of the enzyme aromatase (CYP19) is associated with endocrine pathologies such as osteoporosis, impaired fertility and development of hormone-dependent cancers.
|
20723554 |
2010 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
For women with breast cancer, bone mineral density screening is recommended with long-term aromatase inhibitor use because of the risk of osteoporosis due to estrogen deficiency.
|
29794680 |
2018 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Women diagnosed with breast cancer between 2006 and 2015 and treated with tamoxifen or aromatase inhibitors (n = 36,472) were stratified according to low (without osteoporosis diagnosis nor bisphosphonates exposure) or high (with osteoporosis and/or treated with bisphosphonates) fracture risk.
|
31596961 |
2020 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Osteoporosis treatment, including vitamin D and bisphosphonates, is associated with a 50% reduction of relapse and death in women treated with aromatase inhibitors for ER+ breast cancer.
|
30036740 |
2018 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, CYP17 and CYP19 gene polymorphisms were found to be associated with osteoporosis in postmenopausal women in Turkey.
|
21948762 |
2011 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Osteoporosis is a major side effect of aromatase inhibitors (AIs), which are greatly effective in the treatment of breast cancer.
|
31393399 |
2019 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The osteoporosis incidence in postmenopausal patients on aromatase inhibitors (AI) is much higher than in those on tamoxifen, and adverse effects other than musculoskeletal disorders are less on AI than on tamoxifen.
|
31172521 |
2019 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Osteoporosis (OP) risk factor assessment and bone mineral density (BMD) testing are frequently omitted at baseline in aromatase inhibitor (AI) studies, which may lead to misinterpretation of AI associated bone loss.
|
30939140 |
2019 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We detected four genes (DBP, LRP5, CYP17, and RANK) that showed highly suggestive associations (10,000-permutation derived empirical global p < or = 0.01) with spine BMD/OP; four genes (CYP19, RANK, RANKL, and CYP17) highly suggestive for hip BMD/OP; and four genes (CYP19, BMP2, RANK, and TNFR2) highly suggestive for UD BMD/OP.
|
17002564 |
2006 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Looking for markers related to osteoporosis, we have analyzed five single nucleotide polymorphisms located in genes related to the estrogen pathway, Follicle Stimulating Hormone Receptor (FSHR) gene, the CYP19 aromatase (CYP19A1) gene, the Estrogen Receptor alpha (ESR1) gene, the Estrogen Receptor beta (ESR2) gene and the Nuclear Receptor Interacting Protein 1 (NRIP1) gene in 265 unrelated postmenopausal women.
|
16530497 |
2006 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.
|
14517714 |
2004 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
By reviewing the recent literature, it was found that the genetic variations of CYP19, CYP1A2, CYP3A4, and 17 beta-HSD are important factors affecting the estradiol serum level, and may be closely related to the development of osteoporosis.
|
11360662 |
2000 |
|
Osteoporosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In addition to augmenting the ability of AIs to inhibit BCa growth, calcitriol acting as a selective aromatase modulator that increases aromatase expression in bone would reduce the estrogen deprivation in bone caused by the AIs, thus ameliorating the AI-induced side effect of osteoporosis.
|
19906814 |
2010 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Research on the mechanism of Bushen Jianpi decoction (BJD) for preventing and treating osteoporosis caused by aromatase inhibitors (AI) during treatment for breast cancer resection.
|
27983533 |
2017 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer patients in the MA.27 trial had similar outcomes with steroidal aromatase inhibitor (AI) exemestane and nonsteroidal anastrozole.AIs increase the risk of osteoporosis.
|
28464211 |
2017 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In postmenopausal women with hormone receptor-positive, early-stage breast cancer, treatment with adjuvant aromatase inhibitors is the standard of care, but it increases risk for osteoporosis and fractures.
|
30795951 |
2019 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Aromatase in bone cell: association with osteoporosis in postmenopausal women.
|
7626449 |
1995 |